Julie Cherrington Net Worth

The estimated Net Worth of Julie M Cherrington is at least $2.83 Milion dollars as of 19 January 2022. Julie Cherrington owns over 1,475 units of Mirati Therapeutics Inc stock worth over $149,450 and over the last 5 years he sold MRTX stock worth over $686,928. In addition, he makes $1,990,700 as Independent Director at Mirati Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Julie Cherrington MRTX stock SEC Form 4 insiders trading

Julie has made over 3 trades of the Mirati Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 2,546 units of MRTX stock worth $113,704 on 18 January 2023.

The largest trade he's ever made was selling 2,546 units of Mirati Therapeutics Inc stock on 18 January 2023 worth over $113,704. On average, Julie trades about 502 units every 57 days since 2019. As of 19 January 2022 he still owns at least 2,546 units of Mirati Therapeutics Inc stock.

You can see the complete history of Julie Cherrington stock trades at the bottom of the page.

Julie Cherrington biography

Dr. Julie M. Cherrington Ph.D. serves as Independent Director of the Company. She has served as a member of our Board of Directors since June 2019. Dr. Cherrington is currently the President and Chief Executive Officer of Arch Oncology, Inc. a clinical-stage immuno-oncology company developing novel anti-CD47 mAbs, a position she has held since October 2017. Previously, she has served as President and Chief Executive Officer at several other oncology companies, including Revitope Oncology, Inc. from September 2015 to April 2017, Zenith Epigenetics from 2014 to 2015, and Pathway Therapeutics, a company advancing targeted kinase inhibitors for the treatment of cancer, from 2009 to 2013. In addition, she served as President and Executive Vice President, R&D at Phenomix Corporation. Earlier in her career, Dr. Cherrington was Vice President of Preclinical and Clinical Research at SUGEN, a Pharmacia/Pfizer company. Dr. Cherrington began her career at Gilead Sciences, where she held a range of positions of increasing responsibility. She is also currently on the board of directors of Que Oncology. Dr. Cherrington holds a B.S. in biology and an M.S. in microbiology from the University of California, Davis. She earned a Ph.D. in microbiology and immunology from the University of Minnesota and Stanford University. She completed a postdoctoral fellowship at the University of California, San Francisco.

What is the salary of Julie Cherrington?

As the Independent Director of Mirati Therapeutics Inc, the total compensation of Julie Cherrington at Mirati Therapeutics Inc is $1,990,700. There are 3 executives at Mirati Therapeutics Inc getting paid more, with Charles Baum having the highest compensation of $8,484,390.

How old is Julie Cherrington?

Julie Cherrington is 62, he's been the Independent Director of Mirati Therapeutics Inc since 2019. There are 3 older and 14 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.

What's Julie Cherrington's mailing address?

Julie's mailing address filed with the SEC is C/O MIRATI THERAPEUTICS, INC., 3545 CRAY COURT, SAN DIEGO, CA, 92121.

Insiders trading at Mirati Therapeutics Inc

Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... a Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.

What does Mirati Therapeutics Inc do?

mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.

Complete history of Julie Cherrington stock trades at Mirati Therapeutics Inc a Vaxart Inc

Mirati Therapeutics Inc executives and stock owners

Mirati Therapeutics Inc executives and other stock owners filed with the SEC include:

• Charles Baum,
  President, Chief Executive Officer, Director
• James Christensen,
  Executive Vice President, Chief Scientific Officer
• Faheem Hasnain,
  Chairman of the Board
• Julie Cherrington,
  Independent Director
• Dr. Charles M. Baum M.D., Ph.D.,
  Founder, Pres, Head of R&D and Director
• Dr. James G. Christensen Ph.D.,
  Chief Scientific Officer
• Benjamin J. Hickey M.B.A.,
  Chief Commercial Officer
• Bruce Carter,
  Independent Director
• Craig Johnson,
  Independent Director
• Henry Fuchs,
  Independent Director
• Maya Martinez-Davis,
  Independent Director
• Michael Grey,
  Independent Director
• Aaron Davis,
  Independent Director
• Temre Johnson,
  Director, Investor Relations and Corporate Communications
• Joseph Leveque,
  Chief Medical Officer
• Benjamin Hickey,
  Executive Vice President, Chief Commercial Officer
• Daniel Faga,
  Chief Operating Officer, Executive Vice President
• Michael E. Paolucci,
  Chief People Officer
• Laurie D. Stelzer,
  Chief Financial Officer
• Ryan Asay,
  VP & Head of Corp. Affairs
• Dr. Kelly Covello Ph.D.,
  VP & Head of Medical Affairs
• Kristin Gustafson,
  Chief HR Officer
• Reena R. Desai,
  Gen. Counsel & Corp. Sec.
• Vickie S. Reed,
  Sr. VP & Chief Accounting Officer
• David D. Meek,
  CEO & Director
• Rodney W Lappe,
  Director
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer,
  10% owner
• Asset Management Inc. Boxer,
  10% owner
• Mark J Gergen,
  Exec. VP and COO
• Ltd. Braslyn,
  10% owner
• William R Ringo,
  Director
• Christopher C. Lemasters,
  EVP, Chief Business Officer
• Laurie Stelzer,
  Chief Financial Officer
• Capital, Llc Boxer Asset Ma...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Capital Advisors Llc Aghaza...,
  
• Capital, Llc Braslyn Ltd. B...,
  
• Healthcare Master Fund Ltd ...,
  
• Thirteen Inc. Tuesday,
  10% owner
• Capital, Llc Boxer Asset Ma...,
  
• Maria E Martinez,
  
• Neil Reisman,
  10% owner
• Investors, Llc Mva,
  10% owner
• Shehan Bharatha Dissanayake,
  10% owner
• Bros. Advisors Lpbaker Feli...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital Management Ltd.Bras...,
  
• Capital Partners Lptang Kev...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Martin Godbout,
  Director
• Jamie A Donadio,
  VP of Finance
• Advisors Llc Orbi Med Capit...,
  
• Felixbaker Julian Baker Bro...,
  
• Vickie S Reed,
  SVP, Chief Accounting Officer
• Isan Chen,
  EVP, Chief Medical Officer
• Shalini Sharp,
  
• Capital, Llc Boxer Asset Ma...,
  
• Ltd.Lewis Joseph Braslyn,
  
• Capital, Llc Boxer Asset Ma...,
  
• David D. Meek,
  Chief Executive Officer
• Jamie Christensen,
  EVP & Chief Scientific Officer
• John B Moriarty,
  Chief Legal Officer
• Carol Giltner Gallagher,
  
• Alan B. Sandler,
  Chief Medical Officer
• Aaron I. Davis,
  
• Capital, Llc Boxer Asset Ma...,